secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMEDISYS INC (—)
CIK:        0000896262
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0000896262-25-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amedisys Q1 revenue $594.8M, adj EPS $1.25 vs $1.03 YoY; credit facility extended
--------------------------------------------------------------------------------

- Net service revenue $594.8M (+$23.4M YoY); net income $61.0M ($1.84 diluted) vs $14.4M ($0.44).
- Adjusted EBITDA $68.8M vs $59.9M; adjusted net income $41.6M ($1.25 diluted) vs $33.9M ($1.03).
- Results include $48.1M gain on equity method investment and $16.8M merger-related expenses.
- Fourth Amendment to credit agreement extends maturity to July 30, 2027 and adds Outbound Investment Rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/896262/000089626225000029/0000896262-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/896262/000089626225000029/amed-20250417.htm
  HTML page:      https://secwatch.observer/filing/0000896262-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer